Frespaciguat

Frespaciguat
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2101645-33-2;
Chemical and physical data
Formula	C27H22ClF5N6O3
Molar mass	608.95 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)CCC1=CC=C(C=C1)C2(C(=O)NC=3N=C(N=C(N)C32)C4=NN(C=5C=C(Cl)C=CC45)CCC(F)(F)C(F)(F)F)C C[C@@]1(C=2C(NC1=O)=NC(=NC2N)C=3C=4C(N(CCC(C(F)(F)F)(F)F)N3)=CC(Cl)=CC4)C5=CC=C(CCC(O)=O)C=C5;
	InChI InChI=1S/C27H22ClF5N6O3/c1-25(14-5-2-13(3-6-14)4-9-18(40)41)19-21(34)35-23(36-22(19)37-24(25)42)20-16-8-7-15(28)12-17(16)39(38-20)11-10-26(29,30)27(31,32)33/h2-3,5-8,12H,4,9-11H2,1H3,(H,40,41)(H3,34,35,36,37,42)/t25-/m0/s1; Key:BAFUFNSAYGCZIC-VWLOTQADSA-N;

Frespaciguat (development code MK-5475) is an experimental inhaled soluble guanylate cyclase stimulator developed by Merck for pulmonary arterial hypertension.^[1]^[2]^[3]^[4]

References

^ Bajwa, Ednan K.; Cislak, Dawn; Palcza, John; Feng, Hwa-ping; Messina, Eric J.; Reynders, Tom; Denef, Jean-François; Corcea, Vasile; Lai, Eseng; Stoch, S. Aubrey (January 2023). "Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH)". Respiratory Medicine. 206: 107065. doi:10.1016/j.rmed.2022.107065.
^ Patel, Mahesh J.; Bajwa, Ednan K.; Cislak, Dawn; Palcza, John; Reynders, Tom; Barthson, Jenny; Lai, Eseng; Stoch, S. Aubrey (9 September 2023). "A randomized study to evaluate the effects of single-dose MK-5475 co-administered with sildenafil on systemic hemodynamics". European Respiratory Journal: PA1208. doi:10.1183/13993003.congress-2023.PA1208.
^ El-Kersh, Karim; Jalil, Bilal A. (July 2023). "Pulmonary hypertension inhaled therapies: An updated review". The American Journal of the Medical Sciences. 366 (1): 3–15. doi:10.1016/j.amjms.2023.03.002.
^ Tawa, Masashi; Okamura, Tomio (August 2022). "Factors influencing the soluble guanylate cyclase heme redox state in blood vessels". Vascular Pharmacology. 145: 107023. doi:10.1016/j.vph.2022.107023.